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F O R EWORD  
Evidence-Based Resource Guide 
Series Overview 
The Substance Abuse and Mental Health Services 
Administration (SAMHSA), and specifically, the 
National Mental Health and Substance Use Policy 
Laboratory, is pleased to fulfill the charge of the 21st 
Century Cures Act and disseminate information on 
evidence-based practices and service delivery models 
to prevent substance misuse and help individuals with 
substance use disorders, serious mental illnesses, and 
serious emotional disturbances get the treatment and 
support that they need. 
Individuals in treatment and recovery vary in many 
ways. They experience different mental health and 
substance use conditions, may have co-occurring 
disorders, live in diverse parts of the country, and 
challenge a variety of socio-economic factors that 
help or hinder recovery. These challenges are further 
complicated for individuals who are seeking help for 
mental health or substance use conditions but have 
limited access to effective services. All these factors 
bring complexities to evaluating the effectiveness 
of services, treatments, and supports for mental and 
substance use disorders. 
Despite variations, substantial evidence is available
to inform the types of services, treatments, and 
supports that reduce substance use, reduce severity 
of symptoms of mental illness, and improve 
individuals’ quality of life. Communities are eager 
to take advantage of what has been learned to help 
individuals in need. 
The Evidence-Based Resource Guide Series is a 
comprehensive and modular set of resources intended 
to support health care providers, health care system 
administrators, and community members to meet 
the needs of individuals at risk for, experiencing, 
or recovering from addictions and mental illness.  
An important area of concern for SAMHSA is 
promoting coordinated interventions to address 
first-episode psychosis and co-occurring substance 
misuse and substance use disorders among young 
adults. This guide will review the scientific literature, 
examine emerging and best practices, determine key 
components of peer-reviewed models, and identify 
challenges and gaps in implementation. 
Each guide in the series was developed through input 
from an expert panel made up of federal, state, and 
non-governmental participants. The expert panel 
provided input based on their knowledge of health 
care systems, implementation, evidence-based 
practices, provision of services, and policies that foster 
change. 
Panels included a unique group of accomplished 
scientists, providers, administrators from provider 
and community organizations, federal and state policy 
makers, and persons with lived experience. 
One Piece of a 
Multipronged Approach 
Research shows that implementing evidence-based 
practices requires a comprehensive, multi-pronged 
approach. This guide is one piece of an overall 
approach to implement and sustain change. Users 
are encouraged to review the SAMHSA website for 
additional tools and technical assistance opportunities. 
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Content of the Guide 
This guide contains a foreword and five chapters. The chapters are 
modular and do not need to be read in order. Each chapter is designed 
to be brief and accessible to health care providers, health care system 
administrators, community members, and others working to meet the 
needs of individuals at risk for, experiencing, or recovering from a 
substance use disorder and/or mental illness. The goal of this guide is 
to review the literature on treating substance misuse and substance use 
disorders in the context of first-episode psychosis, distill the research 
into recommendations for practice, and provide examples of the ways 
that these recommendations can be implemented by first-episode 
psychosis treatment programs.
FW Evidence-Based Resource Guide
Series Overview 
Introduction to the series. 
Focus of the Guide 
The transition to adulthood can be a
stressful process for young adults as
they become more self-sufficient and
face important life decisions that can
shape their futures. The transition
to adulthood can be especially
challenging for young people who
experience an emerging serious
mental illness such as first-episode
psychosis and who have a co-
occurring substance use condition.
When first-episode psychosis and
substance misuse occur together,
outcomes tend to be poorer in both
the short and long term. 
For young people experiencing 
first-episode psychosis, reducing or 
stopping substance misuse yields 
significant improvements in psychotic 
symptoms, depressive symptoms, 
and the young person’s ability to 
lead a meaningful life.  Reducing or 
stopping substance use early in the 
experience of psychosis also predicts 
better long-term outcomes. 
Issue Brief
Overview of what is happening in the field. This chapter 
covers challenges to implementing programs. It provides 
descriptions of approaches being used in the field. 
2 What Research Tells Us
Current evidence on effectiveness of programs and practices 
to address first-episode psychosis and co-occurring substance 
use disorders. 
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Examples of Effective Coordinated
Specialty Care Program Models
Sample of Coordinated Specialty Care program models 
that use evidence-based practices to address first-episode 
psychosis and co-occurring substance use disorders. 
Guidance for Selecting and
Implementing Evidence-Based
Practices and Programs
Practical information to consider when selecting and 
implementing programs and practices to address first-episode 
psychosis and co-occurring substance use disorders. 
Resources for Implementation,
Evaluation, and Quality Improvement
Guidance and resources for implementing evidence-based 
programs and practices, monitoring outcomes, and 
improving quality. 
Coordinated Specialty Care (CSC)
is an integrated approach in which
multi-component services are
provided by clinicians with training
and experience in working with young
adults with first-episode psychosis
and their families. This collaborative
approach respects the autonomy and
expertise of young people as part
of the treatment process and allows
young people and their families to
feel better, gain hope for the future,
and move towards recovery. CSC
can support interventions to address
substance misuse and substance use
disorders that are provided alongside
services for first-episode psychosis. 
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C H A P T E R  
1 
ISSUE BRIEF  
First-Episode Psychosis
and Co-Occurring
Substance Use
Disorders 
Background 
In the United States, the transition to adulthood begins 
in the late teenage years and continues through the 
mid- to late-20s. This process can be stressful for 
young people, given that this is a time when they are 
expected to become more self-sufficient and make 
important decisions that can shape their futures. 
Many live on their own for the first time, pursue 
educational goals, start their careers, and enter serious 
relationships.1 These challenges can be much more 
difficult to navigate in the context of an emerging 
serious mental illness, such as first-episode psychosis, 
particularly when a co-occurring substance use 
disorder is also present. 
What is First-Episode 
Psychosis?
Psychosis refers to a condition that makes it difficult 
for an individual to differentiate what is real and 
what is not. When people experience psychosis, 
their thoughts and perceptions are disrupted. They 
may perceive things that others do not or hold strong 
beliefs about things that are not true. Although 
psychosis can be experienced at any age, symptoms 
most commonly begin between the ages of 16 and 30. 
Although the specific definition varies across clinical 
and research settings, first-episode psychosis is 
generally regarded as the early period (up to five years) 
after the onset of psychotic symptoms. In many cases, 
first-episode psychosis impacts young people just at 
the time when they are preparing for and establishing 
autonomy as adults.3 
2 
Psychosis 
A condition that disrupts a person’s thoughts and 
perceptions and makes it difficult for an individual 
to differentiate between what is real and what is 
not. Symptoms of psychosis may include: ⁴ 
■ Delusions (false beliefs) 
■ Hallucinations (seeing or hearing things that 
others do not see or hear) 
■ Incoherent speech 
■ Memory problems 
■ Trouble thinking clearly or concentrating 
■ Disturbed thoughts or perceptions 
■ Difficulty understanding what is real 
■ Poor executive functioning (the ability to use 
information to make decisions) 
■ Behavior that is inappropriate for the situation 
4 
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Disorders 
in which psychosis 
may occur 
Examples of disorders with 
psychosis include: 
■ Schizophrenia 
■ Schizoaffective disorder 
■ Schizophreniform disorder 
■ Brief psychotic disorder 
■ Delusional disorder 
Other disorders, such as major depression 
or bipolar disorder, may include psychosis 
as a severe secondary symptom. 
The first experience of psychosis can be a time of fear, 
stress, and uncertainty for young people and their families. 
Because of the stigma associated with mental illness, many 
young people and their families find themselves alone and 
do not know where to find help or support. 
During this stressful time, young people may also experience 
depression, sleep disruptions, anxiety, and isolation from 
others. Many young people have trouble at school or work 
because it becomes difficult to concentrate and complete 
assigned tasks. School systems and workplaces may also 
lack the capacity to support or accommodate young people 
with psychosis, which can limit their participation in 
education and employment. 
Young people with first-episode psychosis may have 
difficulty maintaining relationships with family and friends 
because they no longer feel safe going out or engaging in 
social activities. Family members and friends may not know 
what psychotic symptoms are or how they can help. Most 
families will not have much information about psychosis, 
so the path towards correct diagnosis and appropriate 
treatment can be long and difficult. The longer symptoms go 
untreated, the greater the risk of additional challenges, such 
as hospitalization or legal problems.5, 6 
Young people in the United States typically experience 
symptoms of psychosis for more than a year before receiving 
treatment. The time between first experiencing psychotic 
symptoms and the beginning of appropriate treatment is 
referred to as the duration of untreated psychosis. It is 
important to reduce the duration of untreated psychosis 
because research shows that the earlier young people find 
and engage in effective treatment, the sooner they may feel 
better and resume activities and goals that are important 
to them.6-9 The shorter the duration of untreated psychosis, 
the greater the likelihood that young adults will experience 
positive outcomes.10 11 , 
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What Are Substance Misuse and Substance Use Disorders? 
There are different ways that people can be affected 
by substance use. Experimentation with substances 
and recreational substance use is common among 
young adults,12,13 and some substance use – such 
as infrequent or moderate drinking – is practiced 
widely and does not cause problems for most people. 
In contrast, substance misuse refers to patterns 
of drinking or drug use that confer higher risk for 
negative consequences. 
Binge drinking, defined as four drinks for women 
or five drinks for men over approximately 2 hours 
(bringing blood alcohol concentration to 0.08 g/ 
dL14), is an example of substance misuse that is 
associated with increased risk of health, interpersonal, 
and cognitive problems in both the short and long 
terms.15-17 Regular marijuana (cannabis) is another 
example of substance misuse that can increase one’s 
risk for health problems and cognitive impairments.18 
For some, substance misuse can develop into a 
substance use disorder. Substance use disorders can 
include the misuse of a variety of drugs including 
alcohol, cannabis, cocaine, heroin, hallucinogens, 
inhalants, opioids, prescription pain relievers, 
tranquilizers, stimulants, and sedatives.19 Individuals 
often experience the negative results of substance 
use disorders over time as their ability to 
function declines.27 
A Substance Use Disorder is defined as 
continued and frequent substance use despite 
experiencing a range of negative consequences, 
including using the substance in larger amounts 
over time, unsuccessful attempts to cut down 
or stop using, spending a lot of time engaged 
in substance use or recovering from its effects, 
and giving up important social, occupational, or 
recreational activities because of substance use. 
Research studies have investigated the impacts of 
specific substances, especially alcohol, cannabis, and 
tobacco, on psychosis symptoms and other health and 
treatment outcomes among people experiencing first-
episode psychosis. 
■ Alcohol use is related to greater non-adherence
to medication, lower quality of life, and reduced
social functioning.20, 21 
Research shows a connection between cannabis
use and psychosis onset for some young adults.22 
While regular cannabis use often predates
the onset of psychosis,23 young adults with
first-episode psychosis who continue to use
cannabis over time are more likely to experience
significantly poorer outcomes than those who
either have never used cannabis or those who
used cannabis but stopped after engaging in
treatment. For these reasons, cannabis use in
particular is a target of treatment in first-episode
psychosis.24-26 
■ Tobacco use is associated with cardiometabolic
problems among young adults with first
episode psychosis and thus is also an important
treatment target.27 
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Among young 
people aged 18-25 
in the United States: 
Approximately 
15.1%
had a substance use disorder 
in 2016¹⁹ 
Of these, about 
6.1%
had a co-occurring mental 
illness and a substance 
use disorder¹⁹ 
and an estimated 
2.1%
had a co-occurring serious
mental illness and a substance 
use disorder in 2016¹⁹ 
13 – 51% 
of young people who have 
first-episode psychosis have 
a co-occurring substance 
use disorder at the start of 
treatment for psychosis20, 28-31 
First-Episode Psychosis
and Co-Occurring
Substance Misuse or 
Substance Use Disorders 
Determining prevalence rates of substance misuse and 
substance use disorders in young adults experiencing first-
episode psychosis is challenging for a number of reasons: 
■ Many studies report prevalence rates for both 
substance use and substance use disorder without 
carefully separating the two; 
■ Studies differ in whether they report current substance 
use or disorder or lifetime substance use or disorder; 
■ Studies assess substance use differently, in that some 
use structured diagnostic interviews and others use 
checklists or less rigorous measures; and 
■ The sample can vary across studies in that some 
include clients who are entering mental health 
treatment, while others include clients who have 
been in treatment for longer periods of time. 
As a result of these methodological differences, we see wide 
variability in prevalence rates of substance use and disorder 
in young adults with first-episode psychosis. 
■ Current substance use is defined as recent use, 
generally in the last month 
■ Current substance use disorder is defined as 
meeting diagnostic criteria during the last 3 months 
■ Lifetime substance use is defined as ever using a 
substance 
■ Lifetime substance use disorder is defined as 
meeting diagnostic criteria during any 12-month 
period other than the last 3 months 
Despite these methodological issues, some conclusions can 
be drawn from the research literature. First, most young 
adults with first-episode psychosis have tried or used 
cannabis, alcohol, or tobacco at some point in their lives.
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Studies have found that 60-80 percent of young adults 
with first-episode psychosis report using cannabis, 88 
percent report using alcohol, and 70 percent report 
using tobacco at some point in their lives.20, 25, 28, 32-34 
These rates are higher but still somewhat in line with 
young adults in the general population (cannabis use: 
61 percent; alcohol use: 86.3 percent).35 
Second, fewer but still many young adults with first-
episode psychosis report use of cannabis, alcohol, and 
tobacco at entry to first-episode psychosis treatment.
Specifically, 24-61 percent of individuals report 
current or recent cannabis use when entering 
treatment, 28-46 percent report current alcohol use, 
and 40-60 percent report current tobacco use.27, 36, 37 
Third, lifetime alcohol and cannabis use disorders 
are fairly common among young adults with first-
episode psychosis. Research consistently finds about 
one-third of young adults with first-episode psychosis 
(28-37 percent) meet criteria for lifetime cannabis 
use disorder and approximately 20-53 percent meet 
criteria for lifetime alcohol use disorder.10, 25, 26, 29, 32, 
38 These rates are higher than what is found among 
young adults in the general population (lifetime drug 
use disorder: 14.2 percent).39 
Fourth, use of other substances such as cocaine, 
opioids, other stimulants, and hallucinogens has been 
less widely studied, but across samples, rates of use 
and disorder appear to be much lower than those 
for cannabis, alcohol, and tobacco.40 One study of 
young adults with first-episode psychosis found that 
20 percent of the sample reported using cocaine and 
29 percent reported using hallucinogens32 at some 
point in their lives. Stimulant use disorder has been 
found in 2-16 percent of young adults with first-
episode psychosis, depending on the sample.10, 26 Other 
research has found low rates of lifetime opioid (3 
percent), cocaine (5 percent), and hallucinogen use 
disorders (5 percent).10 
For young adults experiencing first-episode psychosis, 
having co-occurring substance misuse or a substance 
use disorder makes recovery more challenging. Young 
people who experience both first-episode psychosis 
and a substance use disorder are at particularly 
high risk for a more complicated course of illness,41 
including recurring episodes of psychosis, greater 
risk for later physical health problems, and a greater 
likelihood of future disability.32, 42-44 Research also 
shows that experiencing first-episode psychosis 
together with a substance use disorder is associated 
with a greater number of hospitalizations, higher 
rates of dropout from treatment, a greater degree of 
psychotic symptoms, more medical issues, and 
greater risk of homelessness.42, 45-50 
For example, one study found that young people 
who continued to use cannabis after a first episode 
of psychosis were more likely to have relapses 
of psychosis, even if they were reliably taking 
antipsychotic medications.51 Findings like these 
illustrate the great importance of addressing 
substance misuse and substance use disorders 
among young adults experiencing co-occurring 
first-episode psychosis. 
Substance misuse and substance use disorders can 
also cause significant distress and strife among young 
people with first-episode psychosis and their families. 
Young adults and their families may have conflicting 
views about the benefits and safety of substance use. 
Young people with first-episode psychosis may be 
reluctant or unwilling to stop using substances, which 
may be difficult for families to accept, especially 
when other children are living in the home. Interest in 
reducing substance use may wax and wane over time 
and may be more related to the threat of punishment 
than to any desire to make a change. In some cases, 
young adults with first-episode psychosis may not 
accept that substance use can contribute to  
worsening psychotic symptoms or other poor  
mental health outcomes. 
For young people experiencing first-episode 
psychosis, reducing or stopping substance misuse 
yields significant improvements in psychotic 
symptoms and depressive symptoms and can improve 
a young person’s ability to get back to his or her 
life.25, 52 Research has found that young people who 
stop using substances after a first episode of psychosis 
achieve outcomes similar to those who had never 
used substances.48, 52 Overall, reducing or stopping 
substance use early in the experience of psychosis 
predicts better long-term outcomes. 
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Coordinated 
Specialty Care 
Recovery is possible for young adults who experience 
first-episode psychosis.41, 53 There are effective 
treatments that help young adults reduce and manage 
psychotic symptoms, re-engage with friends and 
families in ways that are comfortable and meaningful 
to them, and work towards their personal future goals. 
Interventions including low doses of antipsychotic 
medications, cognitive and behavioral psychotherapy, 
family education and support, and employment and 
educational supports can help improve psychotic 
symptoms and functioning in their daily lives.3 
These treatments can be provided by a range of 
mental health practitioners in outpatient and 
rehabilitation settings. 
Over the last decade, there has been an important 
national effort to support a multi-element approach 
called Coordinated Specialty Care (CSC), which 
specifically focuses on providing comprehensive 
evidence-based treatment to young people 
experiencing first-episode psychosis. The treatment 
team generally includes a medication prescriber, a 
primary clinician who provides recovery oriented 
behavioral and family services, and an employment/ 
education specialist. Many programs also include 
a peer support specialist with training in recovery-
3 
oriented services and lived experience of first-episode 
psychosis. CSC clinicians are trained to treat first-
episode psychosis, and they work with young people 
and their families to create personal treatment 
plans, ideally as soon as possible after psychotic 
symptoms begin. 
Depending on a young person’s needs and 
preferences, specialists on the team can offer 
psychotherapy, medication management geared to 
first-episode psychosis, case management, family 
education and support, assistance with employment 
or education, and coordination with primary care 
providers. They also conduct community outreach 
and help young people and their families navigate the 
health care system and identify community supports 
and resources. 
Peer support specialists can offer hope that recovery 
is possible and provide an accessible model for how 
to work towards a personal recovery of one’s own. 
Importantly, interventions to address substance misuse 
and substance use disorders are integrated into CSC 
and are provided alongside services for first-episode 
psychosis. This allows young people to address 
substance use goals within the context of first-episode 
psychosis recovery. 
The young person with first-episode psychosis and 
his or her family are central members of the treatment 
team, and services are delivered using a shared 
decision-making framework. This collaborative 
approach respects the autonomy and expertise of 
young people as part of the treatment process and 
allows young people and their families to feel better, 
gain hope for the future, and move towards recovery. 
PERSON 
EXPERIENCING 
PSYCHOSIS 
CASE 
MANAGEMENT 
SUPPORTED 
EMPLOYMENT 
AND 
EDUCATION 
PSYCHOTHERAPY 
PEER SUPPORT 
MEDICATION/ 
PRIMARY CARE 
FAMILY EDUCATION 
AND SUPPPORT 
Coordinated Specialty Care53 
CSC programs that introduce these evidence-
based components over a 2 to 3 year period 
following a first episode of psychosis have been 
shown to have beneficial effects on outcomes 
over time.³ 
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Integration of Treatment Approaches for Substance 
Misuse and Substance Use Disorders in the Context 
of Treatment for First-Episode Psychosis 
Young people experiencing first-episode psychosis, like other young adults, may use alcohol or some drugs 
infrequently or socially and in ways that do not cause problems for them or impair their functioning. However, 
substance use will reach the level of misuse or disorder for some young people experiencing first-episode psychosis. 
It is important to conduct an initial assessment to determine whether a young person uses substances at all, their 
personal patterns of use, and whether substance use is causing problems or impairing functioning.41 Clinicians should 
ask questions that assess the frequency, quantity, and types of substances used and inquire about the young person’s 
specific reasons for use and personal thoughts about change. 
For individuals with psychotic disorders, treatment of substance misuse or substance use disorders by separate, 
unconnected clinicians is rarely effective.54, 55 Poor follow-through on referrals to other agencies for treatment and 
lack of coordination between treatment providers contribute to high rates of dropout from traditional substance use 
treatment for people with psychotic illness. In the last several years, several general principles have emerged as 
important for providing treatment for substance use disorders in the context of first-episode 
psychosis.54 56 57, ,  Research indicates that treatment for co-occurring disorders should be provided in an integrated 
and seamless way.57 
Chapter 2 of this guide provides a review of the literature on treating substance misuse and substance use disorders 
within the context of first-episode psychosis. More research on effective treatments is needed, along with better 
information on how to integrate substance use treatment as part of comprehensive early intervention services, 
particularly for those who have more moderate to severe substance use issues.41, 58 
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Coordinated 
Specialty Care in 
Rural Settings 
Workforce limitations and the lack 
of accessible health care services in 
rural areas can make it challenging to 
implement coordinated specialty care for 
first-episode psychosis. The shortage 
of available staff can be particularly 
pronounced in rural and historically 
underserved areas and providing team-
based treatment across wide geographic 
areas can be difficult. Research 
illustrates the importance of informal and 
formal support networks for individuals 
experiencing co-occurring disorders. 
Telehealth can connect rural and frontier 
providers to program- 
specific expertise.62 
Challenges of Addressing 
Substance Use Disorders 
in the Context of
First-Episode Psychosis 
 1 Screening and Diagnosis 
The effects of alcohol and drugs such as stimulants, 
cannabis, and hallucinogens can mimic symptoms of 
psychotic illness. This can make it difficult to reliably assess 
and diagnose these conditions. Substance use disorders are 
often missed in people with a psychotic illness if routine 
assessment of these issues is not incorporated into 
standard practice.54, 56 
 2 Access to Care 
Not all young people and their families will have access 
to CSC programs. Currently these programs are generally 
located in population centers of over 500,000 people. The 
issue of access affects both youth and adult health systems 
as well as mental health and substance use service systems. 
In addition, a lack of information about first-episode 
psychosis  within the general public and among institutions 
that serve young adults can impede timely access to care 
and may prolong the duration of untreated psychosis.59-61 
Resource-rich programs like CSC may not be widely 
available for young people who need them, particularly in 
rural areas with underserved groups.62 
 3 Lack of Integrated Care 
Fragmentation in service delivery is not uncommon— 
service systems often lack structural relationships necessary 
to coordinate the delivery of services.63 If mental health 
services and substance use services are distinct, there may 
be less coordinated care for individuals who experience 
psychosis and substance use disorders.
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WHAT RESEARCH TELLS US 
Effectiveness of Treatment for Substance
Use Disorders Among Persons with
First-Episode Psychosis 
Introduction 
As reviewed in Chapter 1, substance misuse and 
substance use disorders (referred to throughout as 
“substance misuse/disorders”), especially those  
related to alcohol and cannabis, are common among 
young adults entering treatment for first-episode 
psychosis. As a result, addressing substance misuse/ 
disorders is an important component of first-episode 
psychosis treatment. 
The literature in this area contains two types of 
studies. The first are naturalistic studies that follow 
young people over time to examine the course of 
substance use following first-episode psychosis 
services. The second are randomized controlled trials 
that test interventions specifically targeting substance 
misuse/disorders to determine which interventions are 
most effective in reducing substance use and improving 
related areas of functioning. 
In order to fully understand the ways that substance 
misuse/disorders change over time in response to 
treatment, it is important to review both types of studies. 
This chapter has several goals: 
■ We present findings on changes in substance 
misuse/disorders in response to generalized 
treatment for first-episode psychosis. 
■ We review research that examines the impact 
of targeted interventions for substance misuse/ 
disorders on substance use outcomes. 
■ We review research that examines the impact 
of targeted interventions for substance misuse/ 
disorders on other important outcomes. 
■ We synthesize the findings in order to make 
recommendations for addressing substance misuse/ 
disorders when working with young adults with 
first-episode psychosis. 
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Changes in Substance Use in Response to Generalized 
Treatment for First-Episode Psychosis 
Generalized treatment for first-episode psychosis 
usually includes low doses of antipsychotic 
medications, psycho-education about psychosis and 
recovery, cognitive and behavioral psychotherapy, 
family education and support, and employment and 
educational supports. As part of psycho-education, 
many first-episode psychosis treatment programs 
highlight the relationship between continued 
substance use and poorer outcomes and advise young 
adults to reduce or stop substance use in order to 
promote recovery. However, these services generally 
do not include specialized interventions for substance 
misuse/disorders. 
Most research in this area follows young adult 
samples engaged in first-episode psychosis treatment 
naturalistically to observe if and how substance use 
changes over time once treatment for psychosis is 
provided. In 2011, Wisdom and colleagues1 reviewed 
this literature, including nine naturalistic studies 
that followed cohorts of young adults entering early 
psychosis treatment, sometimes for several years. 
These studies showed that approximately 50 percent 
of young people decrease substance use after receiving 
generalist services for first-episode psychosis, often in 
the initial weeks or months of treatment. 
Research has not fully addressed how generalized 
first-episode psychosis treatment impacts 
reductions in substance use. It could be that this 
type of comprehensive, integrated treatment 
encourages behaviors that support recovery and 
discourages those that do not. Another possibility 
is that young adults who experience psychosis 
attribute symptoms to substance use and stop use 
in response. 
The one randomized controlled trial in this literature 
– a comparison of participation in a specialized 
psychosis relapse prevention program that emphasized 
abstinence from substances versus a generalized early 
psychosis treatment as usual – found no differences on 
any substance use outcome measures.2 
Lobbana and colleagues conducted a qualitative 
study in which they asked young adults who were 
engaged in first-episode psychosis services and had 
used substances prior to treatment about factors 
that influenced their substance use. One theme 
that emerged was that changes in life goals affected 
3 
substance use. Many young adults in the sample 
reported that values such as health, income, and 
family increased in importance over time and were 
key reasons for reducing or stopping substance use. In 
synthesizing the findings of their review, Wisdom and 
colleagues speculate that many influences are likely 
at work: “Experience, education, treatment, or other 
factors led many clients to curtail their substance use 
disorders after a first episode of psychosis.”1 
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Effectiveness of
Targeted Interventions on 
Substance Use Outcomes 
Research in this area is focused on studying interventions that 
specifically address substance misuse/disorders. The studies 
in this section are all randomized controlled trials, the highest 
standard for examining intervention efficacy. Unless otherwise 
noted, all studies reviewed in this section included: 
■ A sample of individuals with first-episode or early 
psychosis; 
■ An intervention or intervention model that addresses 
substance misuse/disorders; 
■ An outcome measure pertaining to substance 
use (e.g., toxicology report, participant self-report); and 
■ A comparison group. 
Overall, nine randomized controlled trials have been 
conducted to test the effects of specific interventions targeting 
substance use in young adults with first-episode psychosis,4-12 
including brief motivational enhancement plus skills training 
interventions, cognitive behavioral therapy plus motivational 
interviewing, and antipsychotic medication. 
This section uses a four-tiered
rating system to assess the quality
of the evidence.
S 
Strong evidence of
effectiveness 
Effectiveness demonstrated in
systematic reviews or meta-analyses
of randomized controlled trials. 
M 
Moderate evidence of
effectiveness
Effectiveness demonstrated in at 
least two randomized controlled 
trials judged to be of sufficient 
methodological quality. 
L 
Limited evidence of
effectiveness
Effectiveness demonstrated in: 
one randomized controlled 
trial, OR 
■ at least two quasi-experimental 
studies with a matched control 
group and a design that attempts 
to isolate the effects of the 
intervention, OR 
■ results across studies (whether 
randomized controlled trial or 
quasi-experimental) are mixed or 
randomized controlled trials show 
non-significant average effects 
in meta-analyses or are limited 
by significant methodological 
problems (e.g., inadequate 
sample size). 
N 
No evidence of effectiveness 
Effectiveness not demonstrated in any
study (regardless of study design). 
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Brief Motivational Enhancement/Skills Training 
Brief motivational enhancement/skills training is a treatment approach that helps individuals overcome ambivalence 
and develop skills needed to reduce or stop substance use. Studies of brief motivational enhancement/skills training for 
individuals with first-episode psychosis tested the intervention primarily in an individual format over four to nine sessions.5, 9 
Cognitive Behavioral Therapy (CBT) + Motivational Interviewing (MI) 
Cognitive behavioral therapy (CBT) + motivational interviewing (MI) combines CBT techniques, such as the development 
of a shared formulation of substance use problems, psychoeducation about the relationship between substance use and 
psychosis, goal setting and change planning, coping skills training, and motivational enhancement in order to address 
substance use problems. Most studies of CBT + MI for individuals with first-episode psychosis evaluated the intervention in 
an individual format over 10 or more sessions, with several offering at least one booster session.4, 6, 8, 10, 11 
Antipsychotic Medications 
Antipsychotic medications, such as olanzapine and risperidone, have also been evaluated for their impact on substance 
use outcomes among individuals with first-episode psychosis.  
Brief Motivational  
Enhancement/Skills Training 
Cognitive Behavioral Therapy +
Motivational Interviewing
S L M N S L M N 
Two randomized controlled trials demonstrated that 
brief motivational enhancement plus skills training 
interventions were associated with significantly 
greater reductions in substance use than treatment 
as usual (i.e., generalized treatment for first-episode 
psychosis) in samples of young adults with first-
episode psychosis.5, 9 However, one of these studies 
had a small sample size,9 and the other study 
demonstrated that differences between treatment 
and control groups were no longer significant at a 
12-month follow-up.5 
These findings suggest that interventions that 
incorporate brief motivational enhancement and skills 
training hold promise for improving substance use 
outcomes. Additional research in larger samples is 
needed to more fully understand the effects of brief 
motivational enhancement and skills training on 
substance use outcomes, and to determine its optimal 
dose. The fact that benefits have been found to 
decrease over time suggests that people may 
need boosters or ongoing support for reducing 
substance use. 
Five randomized controlled trials found that 
cognitive behavioral therapy (CBT) plus motivational 
interviewing (MI) was no more effective than a 
comparison treatment (including psychoeducation 
or time-limited interventions) in terms of reducing 
substance use among individuals with first-episode 
psychosis.4, 6-8, 11 Some of these studies included active 
control conditions that provided generalized early 
psychosis services. As reviewed above, such services 
are associated with reduced substance use over time 
for some individuals. 
One small randomized controlled trial of brief CBT
plus MI, delivered over four to six sessions, showed 
that the treatment group experienced significant 
declines in the frequency of cannabis and alcohol 
abuse compared to those in a treatment as usual 
condition.10 Taken together, these results provide 
limited evidence for brief CBT plus MI when 
compared to treatment as usual, while more extended 
CBT/MI interventions do not appear to be any more 
effective than briefer ones that address substance use. 
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Pharmacological Interventions
S L M N 
Pharmacological treatments for substance misuse 
among individuals with first-episode psychosis 
have also been studied. One randomized controlled 
trial found that there were no differences between 
those being prescribed risperidone and those being 
prescribed olanzapine in terms of cannabis and 
alcohol use;  in both groups, the use of substances 
during the study was substantial (38-52 percent). 
12
A systematic review and meta-analysis of the efficacy, 
acceptability, and tolerability of various antipsychotic 
medications among individuals with schizophrenia 
and co-occurring substance use indicated that: 
■ Clozapine was superior to other antipsychotics 
in terms of reducing substance use. 
■ Risperidone was shown to be more effective 
than olanzapine for reducing cravings.13 
The majority of these studies were conducted with 
individuals with chronic schizophrenia, suggesting 
that additional research on the impact of antipsychotic 
medications on substance use outcomes among people 
with first-episode psychosis is needed. 
Other pharmacological interventions for substance 
use, such as the antioxidant N-acetylcysteine, 
demonstrate effectiveness among adolescents with 
cannabis dependence14 but have also not been studied 
among individuals with first-episode psychosis and 
co-occurring substance misuse or substance 
use disorder. These interventions have either 
targeted non-specific substance use (i.e., alcohol, 
cannabis, street or non-prescribed drugs, tobacco6, 9, 
10) or cannabis use in particular.4, 5, 7, 8, 11, 12 Although 
Medication-Assisted Treatment (MAT) is considered 
the gold standard for the treatment of some substance 
use disorders, no studies have yet examined its use 
for individuals with first-episode psychosis who have 
co-occurring substance use disorders. Further study 
of interventions for specific substances in randomized 
controlled trials is recommended. 
Interventions for Individuals with 
First-Episode Psychosis and Substance 
Misuse/Disorders 
Seven studies included in this review tested the 
effects of the intervention only among individuals 
with first-episode psychosis who also had 
substance misuse or qualified for a substance use 
disorder at the beginning of the study.4, 5, 7-11 Four 
studies included both people with and without 
current substance misuse.2, 6, 12, 15 Out of these 
four studies, one demonstrated greater substance 
use among those who were using versus those 
who stopped use prior to study entry,12 one 
demonstrated no differences across subgroups 
with varying levels of substance use,6 and two 
did not compare outcomes based on frequency 
or severity of substance use at baseline.2, 15 
Identifying the most effective substance use 
treatments in samples of those with first-episode 
psychosis with varying levels of substance use is 
a critical area for future research. 
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Controlled Trials of Targeted Interventions on 
Functional Outcomes 
Some studies of substance use treatments have reported on non-substance use outcomes in order to shed light on 
whether these interventions might impact areas such as symptoms, hospitalization, and functional outcomes. 
Brief Motivational  
Enhancement/Skills Training 
Cognitive Behavioral Therapy + 
Motivational Interviewing 
S L M N S L M N 
Brief motivational enhancement and skills training 
interventions have been shown to be no more effective 
than treatment as usual for improving symptoms, 
social/occupational functioning, or global functioning; 
or for reducing hospitalizations.5 
Randomized controlled trials of cognitive behavioral 
therapy plus motivational interviewing have 
demonstrated positive findings related to self-
efficacy,10 mixed findings related to quality of life, 
symptoms, and social/occupational functioning,4, 6-8, 
10, 11 and negative findings related to neurocognition, 
insight, attitudes toward treatment, global functioning, 
hospitalizations, and psychosis relapse rates.4, 11 
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Using the Evidence to Guide Practice 
There are several conclusions that can be drawn from 
this review. 
1 
Young adults experiencing first-episode 
psychosis, even those who enter treatment 
with substance misuse or substance use 
disorder, should be offered generalized 
early intervention services. Many will make 
significant reductions in substance misuse/ 
disorder in the early stages of first-episode 
psychosis treatment without the need for 
any additional targeted treatment. 
2 
Those who do not reduce their substance 
use in response to generalized first-episode 
psychosis treatment should be offered 
targeted substance use interventions. There 
is limited evidence that brief interventions 
that include motivational enhancement, 
skills training, and cognitive behavioral 
therapy are beneficial. As we await a 
more robust evidence base, use of these 
interventions is encouraged, but they may 
not be sufficient to significantly and quickly
reduce substance use. 
 
The process of engaging these young 
adults in substance use treatment is 
likely a longer-term process that unfolds 
over time as treatment for first-episode 
psychosis helps young people feel better 
and identify reasons for change. Treatment 
focused on addressing problems associated 
with substance use (e.g., social issues, 
physical health problems, medication 
adherence) may be most appropriate for 
those not ready to reduce or stop substance 
use.4 Time-limited interventions for 
substance use might be considered before 
implementing longer, more elaborate 
treatments.5, 7, 9, 10 
3 
It is clear from this review that more 
research needs to be done to build an 
evidence base for intervention in this area; 
there are relatively few studies, and they 
vary considerably in approach. In spite of 
this diversity, the interventions that have 
been studied share a number of common 
elements in their approach to substance use 
treatment. These include: 
Harm reduction approach – the intervention 
aims to reduce the negative consequences 
associated with substance use and to support 
person-centered goals related to decreasing in 
addition to stopping substance use. 
Decision support materials – the 
intervention includes educational materials, such 
as informational leaflets about the relationship 
between psychosis and substance use, as well as 
decision support tools (e.g., decisional balance 
worksheets) to help individuals weigh the pros 
and cons of various options associated with 
substance use. 
Focus on interests and life goals – the 
intervention assesses individuals’ life and 
community participation interests and goals in 
areas such as work/school, social relationships, 
leisure/recreation, spirituality, and health in 
order to build rapport, facilitate engagement, 
and help individuals note discrepancies between 
substance use and goal attainment. 
Motivational enhancement – the 
intervention uses motivational interviewing 
techniques, such as open-ended questioning, 
affirmations, reflections, and summaries to 
help individuals overcome ambivalence about 
making a change related to substance use. 
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■ Adaptations for individuals with 
cognitive challenges – the intervention 
uses strategies such as frequent repetition, 
simple and concise language, written aids, 
and concrete metaphors in order to engage 
individuals with cognitive challenges in 
motivational interviewing. 
■ Establishing goals for change and 
change plans – in addition to assessing life 
goals, the intervention assists individuals with 
developing specific goals and plans related 
to substance use that are appropriate to their 
current stage of change. 
■ Coping skills training – the intervention 
helps individuals develop coping strategies 
such as avoiding or leaving high risk situations, 
increasing enjoyable activities not involving 
substance use, and obtaining support from others 
in order to change substance use. 
■ Relapse prevention planning and 
problem solving – the intervention encourages 
individuals to anticipate challenges to short-
term achievement and long-term maintenance 
of substance use change and teaches problem 
solving skills to address these challenges. 
■ Communication among all team 
members regarding individuals’ goals 
and plans – all members of the treatment team 
are informed of individuals’ goals and progress 
related to changing substance use so that they 
can reinforce and support individuals in this area 
as a regular part of their work together. 
■ Follow-up support – booster sessions that 
are consistent with individuals’ current stage of 
change are offered, reinforcing change attempts, 
refining skills, and further developing relapse 
prevention plans. 
Incorporating these elements can help clinicians talk 
about substance misuse with their young adult clients 
and maintain these conversations as part of the first-
episode psychosis treatment process. It may be that 
these ongoing discussions have the best chance of 
supporting change. Adding contingency management, 
peer support, and family-based approaches to 
substance use treatment may also be tried to boost 
effectiveness.4, 8 
As noted, the literature does not yet fully address 
the efficacy of medications such as clozapine 
for treatment of substance use disorders in those 
experiencing first-episode psychosis. Drawing upon 
their knowledge and experience, program prescribers 
can consider findings in studies involving other 
populations, such as adults, and integrate them in 
making prescribing decisions with individuals with 
first-episode psychosis. Although these strategies 
do not yet have empirical support in first-episode 
psychosis, there is support for their positive impact in 
other populations of individuals with substance use 
disorders.16-20 
General Questions for evaluating 
substance use disorders. 
Ask about: 
• Alcohol use: drinks per/day, drinks per/week, 
– Binge drinking Men:> 5/,women W > 4 
drinks in approx. 2 hour time period 
– Heavy drinking: binge use on 5 or more 
days in past month (see  Pocket guide for 
Alcohol Screening and Brief Intervention21 
• Use of prescription drugs for a non-medical 
reason/for a purpose not part of why prescribed 
• Use of any illicit substance (see TAPS)22 
• Symptoms of depression Patient Health 
Questionaire (PHQ)-9, PHQ-2 
– Interest, pleasure, depressed mood, energy, 
appetite, concentration, guilt, motor activity, 
thoughts of hurting self 
– PHQ-2: loss of interest/pleasure, depressed/ 
hopeless (see PHQ 9)23,24 
• Follow up on positive responses for all above 
questions 
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C H A P T E R  
3 
EXAMPLES OF EFFECTIVE COORDINATED
SPECIALTY CARE PROGRAM MODELS 
Evidence-Based Programs for Implementing
Integrated Treatment of Substance Use Disorders
and First-Episode Psychosis
This chapter highlights three models of Coordinated 
Specialty Care (CSC) that provide integrated 
treatment of substance misuse and substance use 
disorders (referred to throughout as “substance 
misuse/disorders”) to people experiencing first-
episode psychosis. 
Each model has its own manual or guidance 
procedures related to the treatment of substance 
misuse/disorders, resulting in variations in the way 
this treatment is provided across programs. However, 
across these models, CSC programs use many of 
the common elements of substance use treatment 
that were identified in Chapter 2, including a harm 
reduction approach, with a focus on individuals’ 
interests and life goals, coping skills training, and 
relapse prevention planning. 
Currently, there are no data comparing substance 
use outcomes across these CSC models. However, 
research supports that treatment for co-occurring 
disorders should be provided in an integrated way, and 
these model descriptions exemplify how this may be 
accomplished in practice. 
Choosing Programs 
Although there are other excellent CSC models, the 
models featured in this chapter were chosen because 
they have a clearly articulated, standardized approach 
to substance use treatment and are representative of  
the most prevalent and well-developed CSC models  
to date. 
Format of the Chapter 
Following is a succinct description of each of the three 
models, including model-specific features, substance 
use treatment elements, sample implementation 
strategies from CSC programs associated with the 
model, sample recovery outcomes, and data on 
substance use from the model. The format of each 
description is uniform to enable the reader to quickly 
find and compare information across models. 
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 A harm reduction approach is considered to be a desired 
practice that clinicians should be trained in implementing. 
This is assessed at fidelity reviews of the practice 
guidelines. 
 
 
 
 
 
  
 
 
 
 
 
Model Description
EASA is a network of programs and 
individuals across Oregon focused on 
providing rapid identification, support, 
assessment, and treatment for individuals 
ages 12-25 who are experiencing early 
signs of psychosis. EASA is designed as 
a transitional program, with the goal of 
providing the education and resources the 
person needs to be successful in the long-
term. Most individuals participate in EASA  
for about two years, although that time  
frame varies. 
Model’s Substance Use 
Disorder Treatment 
Elements 
Treatment team members share in 
addressing substance use by integrating 
substance use treatment into multiple 
services, including: 
1. Cognitive Behavioral Therapy for 
psychosis, substance use disorders, 
and other conditions; 
2. Multiple Family Group 
Psychoeducation Groups; 
3. Motivational Interviewing; 
4. Peer Support (mental health, substance 
use, family); 
5. Supported Employment and Education; 
6. Case Management; and 
7. Feedback Informed Treatment. 
All practices are listed in EASA Practice 
Guidelines: 
http://www.easacommunity.org/PDF/ 
Practice%20Guidelines%202013.pdf 
Model #1: The Early 
Assessment and Support 
Alliance (EASA) 
The EASA Center for Excellence provides training, support, 
and resources for program development and quality 
improvement for EASA programs across Oregon as well as 
for national programs. The EASA Center for Excellence is a 
collaboration between Portland State University and Oregon 
Health & Science University. For information regarding 
EASA, visit www.easacommunity.org. 
Sample Implementation Strategies 
1. All clinicians engaging in assessment and treatment 
receive training in the Structured Interview for DSM-5 
Disorders (SCID 5). This a comprehensive assessment of 
common mental health conditions including substance 
use disorders. 
2. The SCID 5 along with advanced monthly diagnostic 
consultation supports clinicians in determining if the 
participant has a primary substance use disorder, a 
substance-induced disorder, or a co-occurring disorder. 
Consultation is offered, as clinicians often struggle with 
differential diagnosis and subsequent treatment when a 
client presents with symptoms of both substance use and 
mental illness. 
3.
4. As part of the EASA credentialing process, clinicians 
across disciplines are encouraged to become trained in 
Motivational Interviewing. For more information about 
training, see: http://www.easacommunity.org/PDF/ 
Certification_Rubric_2018.pdf. 
5. EASA teams, including clinicians treating substance use 
disorders, meet weekly and review the goals of every 
enrolled client. This ensures communication across the 
team about substance use goals. 
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Sample Recovery Outcomes 
1. Shared treatment plans are developed based on diagnosis, client goals, motivation for change, and current 
strengths/support (as identified by a strengths assessment based on the University of Kansas model). Treatment 
plans are completed in coordination with the family if the client grants permission for the family to be involved. 
2. The Individual Placement and Support model of Supported Employment and Education is offered to all 
participants who have education and employment goals regardless of current substance use. 
3. Clinicians and clients develop a process for talking about substance use that is collaborative and trusting. 
Data from the Model 
EASA collects longitudinal data regarding substance use outcomes and outcomes in related areas of  
functioning. Based on 2018 data, young people: 
EASA 
Decrease Substance Abuse 
23.8% had an alcohol use disorder 
or problems with alcohol at intake, 
compared to 9.2% with a diagnosis 
of alcohol use disorder or problems 
with alcohol reported at discharge. 
37.8% had a diagnosis of other 
substance use disorder or problems 
at intake, compared to 14% with a 
diagnosis of other substance use 
disorder or problems reported at 
discharge. 
Maintain or Enter School or Work 
31.5% were in school or employed 
at intake AND discharge (no change 
in occupational functioning over the 
course of treatment). 
18.9% were not in school or 
employed at intake but were in 
school or employed at discharge. 
This data reflects outcomes for all patents discharged in 2018, not just those who went through both intake and 
discharge within the year.  Most clients are enrolled in EASA for at least two years. 
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Model Description 
EDAPT programs provide comprehensive 
outpatient services to individuals ages 12-40 
who have experienced: 
1. The recent onset of affective or 
nonaffective psychosis (within the past 2 
years); or 
2. Clinical high risk for psychosis. Treatment 
includes case management, ongoing 
psychiatric and/or medical assessments 
and treatment, client and family 
psychoeducation and psychotherapy, 
educational and vocational support, and 
relapse prevention. 
EDAPT also includes peer and family 
advocacy and support, trauma-integrated 
care, substance abuse management, 
Cognitive Behavioral Therapy for Psychosis, 
Family Focused Treatment, and cognitive 
remediation. 
Model’s Substance Use
Disorder Treatment
Elements 
To specifically address substance misuse, 
EDAPT uses the Substance Abuse 
Management Module (SAMM) group,6 which: 
1. Provides psychoeducation on the 
role substances play in exacerbating 
symptoms and decreasing functioning; 
2. Guides group members in problem 
solving around substance use; 
3. Teaches coping skills from a variety of 
theoretical orientations (e.g. cognitive 
behavioral therapy, dialectical behavior 
therapy) to support abstinence OR 
harm reduction; and 
4. Helps the client develop a plan to 
prevent relapse. 
Model #2: Early Diagnosis 
and Preventive Treatment 
(EDAPT) 
EDAPT programs are in Sacramento, Fairfield, and Napa, 
California. For more information see: https://earlypsychosis. 
ucdavis.edu. 
Sample Implementation Strategies 
1. EDAPT teams conduct a thorough intake evaluation 
through record review and the Structured Clinical 
Interview for DSM-5 (SCID 5) with the individual and 
primary support persons. 
2. Teams use motivational enhancement as needed to 
support change. 
3. EDAPT’s focus on group treatment for substance use 
was difficult because not all clients wanted to attend, 
and schedules/transportation were a barrier. So, EDAPT
used more SAMM components in individual and family 
treatment and encouraged SAMM group participation. 
4. EDAPT teams integrated dialectical behavior therapy 
(DBT) skills into their approach to enhance distress 
tolerance and resiliency. 
Sample Recovery Outcomes 
1. Substance use goals are included in the client’s treatment 
plan, and CSC team members support these goals. 
2. Using a cognitive behavioral framework to understand the 
role of substance use, teams strive to find alternative ways 
to support life goals. 
3. The SAMM group format gives clients the opportunity 
to provide each other peer support and support progress 
toward treatment goals. 
4. EDAPT’s family-centered treatment approach empowers 
individuals and their support systems to be active 
participants in care and support individuals’ personal, 
social, educational, and occupational goals. 
5. EDAPT’s diverse treatment team adapts to the needs 
of clients and families in a culturally sensitive manner. 
EDAPT uses home and school visits, bilingual clinicians, 
and interpretation services. EDAPT involves families and 
consumer advocates, who use their own experience to 
engage, educate, and motivate others. 
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Data from the Model 
EDAPT collects data on substance use at intake, the number of clients who receive substance use treatment, and 
outcomes related to symptoms and functioning. Based on data from clients enrolled in EDAPT over one year: 
1 
2 
3 
56% reported a history of substance use, 31.6% reported current use, and 23.7% met criteria for a 
substance use disorder at intake. Substance use at intake was associated with significantly lower 
role functioning on the Global Functioning: Role Scale. 
All individuals with identified substance use issues at intake received some exposure to substance use 
treatment. 
■ 60.5% were identified at intake as having substance use issues that merited treatment and 
were invited to participate in SAMM group, and of these 30% participated in SAMM 
■ Discussions about substance use were incorporated into treatment (based on SAMM harm reduction 
model) regardless of participation in SAMM group 
Over 12 months of care, clients with 
identified substance use issues at intake 
(receiving SAMM and not receiving SAMM) 
demonstrated improvement in 
functioning, as assessed by the Global 
Functioning Scale (GAF). 
Over 12 months of care, clients with identified substance use issues at intake (receiving SAMM and not 
receiving SAMM) showed a reduction in symptom severity across domains on the Clinical Global 
Impressions (CGI) scale, with the most notable changes observed on positive and overall symptoms. 
4 
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Model Description 
The PIER model treats the earliest 
symptoms of mental illness. It was 
developed on a foundation of ongoing 
research that indicates that early mental 
illness can be markedly altered or 
reversed by earlier treatment. Through a 
combination of family psychoeducation, 
supported education and employment, 
and pharmacologic treatment, the PIER 
model has a powerful effect in reducing 
the symptoms that place a young person 
at risk for the onset and severe disabilities 
of mental illness. In addition to the PIER 
model’s use of evidence-based treatments, 
the critical feature of this approach is 
community outreach by a clinical team to 
school professionals, general practitioners, 
pediatricians, and other key groups to 
educate and inform about the early signs of 
mental illness. PIER prioritizes the treatment 
of psychosis in order to reduce substance 
use disorders but offers specialized 
substance use disorder treatment if needed. 
Model’s Substance Use
Disorder Treatment
Elements 
1. The PIER model assumes that substance 
misuse among people with a psychotic 
disorder is largely the result of the 
disorder. Emphasis in PIER is thus on 
addressing psychosis and improving 
functional recovery. Treatment of 
substance use is implemented as it 
relates to these aims. For example,  
family psychoeducation includes a 
discussion about substance use in 
the context of symptom reduction and 
functional improvement. 
2. Substance use treatment within PIER is 
based on motivational interviewing and 
cognitive behavioral approaches and 
follows a harm reduction model. 
Model #3: Portland 
Identification and Early 
Referral (PIER) Program 
PIER manuals and other materials are available at http://www. 
piertraining.com/resources/. 
Sample Implementation Strategies 
According to the PIER program in Portland, Maine: 
1. The program has consistently had a certified substance 
abuse counselor on staff to ensure continued capacity to 
treat substance misuse/disorders within the program. 
2. The multifamily group approach includes systematic 
application of problem solving derived from cognitive 
behavioral therapy. If substance misuse is identified as an 
issue, it is focused on until the problem is resolved. 
According to the PIER program in Delaware: 
1. The National Outcome Measures (NOMS) instrument, 
which includes items on past 30 day use of substances, is 
used to identify people with current substance use at intake 
and to track progress over time. 
2. Program staff use the Adolescent Community 
Reinforcement Approach (A-CRA),7 which is a 
behavioral intervention that aims to replace environmental 
contingencies supporting substance misuse with pro-social 
activities and behaviors supporting recovery. As part of 
this approach, clients are assisted with weighing the pros 
and cons of substance use and developing communication, 
problem solving, and relapse prevention skills. 
3. The program includes a structured group program focused 
on prevention of substance misuse, called Towards No 
Drug Abuse (TND) (https://tnd.usc.edu/). Components 
of this program include building motivation/motivational 
interviewing, social conversation skills, and rational 
decision-making. 
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Sample Recovery Outcomes 
1. PIER does not screen out people with substance misuse/disorder from the program, except in 
extreme circumstances. 
2. PIER staff respect the autonomy of clients while helping them consider the pros and cons of substance use. 
3. Staff use a non-judgmental approach to ensure that clients are comfortable talking about substance use. 
4. During family psychoeducation, individuals who have made progress with reducing use can support others in 
their recovery by sharing their experiences. 
Data from the Model 
Based on the Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP) clinical trial,8 
which tested the effectiveness of the PIER approach at six sites from 2007 to 2010: 
PIER 
Substance Misuse 
11% of those experiencing first-
episode psychosis, and 7% of those 
at clinical high risk for psychosis 
met criteria for substance 
misuse at baseline. 
Participation in 
Work or School 
Over a 24-month period, those 
receiving treatment based on the 
PIER model increased their 
level of participation in work 
or school by 21% compared to 
7% in the community care group. 
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C H A P T E R  
4 
Guidance for Implementing
Evidence-Based
Practices
Prior chapters in this guide have given an overview of 
what is known about the course of substance misuse 
and substance use disorders (referred to throughout 
as “substance misuse/disorders”) in the context 
of first-episode psychosis services, what research 
tells us about the efficacy of specific interventions, 
and illustrations of different ways that Coordinated 
Specialty Care (CSC) models and programs have 
used the research findings to guide clinical practice. 
A common set of strategies to guide treatment for 
substance misuse/disorders in first-episode psychosis 
treatment programs has been identified. 
2. To identify common implementation barriers and 
potential solutions to address them. 
Because the intersection of substance misuse and first-
episode psychosis treatment is complex, programs 
guided by the different CSC models have used varied 
approaches to implement substance misuse/disorders 
interventions. The next step is to translate these 
experiences into practical guidance for implementing 
substance misuse/disorders interventions in real-world 
settings by clinicians and program administrators 
tasked with helping support recovery in young adults 
with first-episode psychosis and their families. 
This chapter has two goals:  
1. To describe implementation strategies that 
clinicians and programs can use to successfully 
offer substance misuse/disorders treatment within 
first-episode psychosis services; and 
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Implementation 
Strategies and Tasks 
!1 Implementation Strategy #1
Create a program culture that 
supports treatment for substance 
misuse and substance use disorders
■■ Identify substance misuse/disorders as 
a treatment priority within first-episode 
psychosis services 
■■ Consider the population served by the 
program and make sure the necessary 
treatment resources are available within the 
program or the surrounding community 
■■ Integrate a harm reduction approach to 
substance misuse/disorders into first-episode 
psychosis services 
There are a number of decisions that 
administrators and clinicians can make to create 
a program culture that supports treatment for 
substance misuse/disorders within first-episode 
psychosis services. A first task is for leadership 
of first-episode psychosis treatment programs  
to communicate the clear treatment need,  
and identify substance misuse/disorders as  
a treatment priority. Key messages to 
disseminate include: 
■ More than half of young adults with 
first-episode psychosis currently are or 
have been affected by substance misuse/ 
disorders in the past; 
■ Evidence supports integrated early 
intervention services for these young 
adults; and 
■ Young adult treatment outcomes are better 
when services are provided by a team that 
understands first-episode psychosis and 
integrates school, work, family, and 
recovery services.1 
Addressing a problem as complex as substance 
misuse/disorders can be especially challenging 
for first-episode psychosis treatment programs 
challenged by time, limited resources, and 
other constraints. Nevertheless, it is critical 
that programs treating individuals experiencing 
first-episode psychosis prioritize substance 
use treatment identification and care and build 
treatment for substance misuse/disorders 
into the array of services offered by various 
members of the treatment team. 
A second essential task is coordinating first-
episode psychosis and specialty substance use 
disorder services to ensure integrated treatment 
across programs and build connections and 
referral relationships with community treatment 
programs based on program participants’ 
needs and culture. Such linkages can augment 
treatment and provide more intensive or 
complementary services. 
For example, clients of first-episode psychosis 
programs without the capacity to effectively 
treat severe substance use disorders that are 
affecting all aspects of a client’s functioning 
(including tolerance and withdrawal as core 
symptoms) may be better served by initial 
enrollment in detoxification, inpatient, or 
residential substance use disorder treatment. 
First-episode psychosis programs located in 
communities with high rates of heroin use 
and opioid use disorder will need to have 
■ Overall, CSC models identify substance misuse/ 
disorders as common issues within first-episode 
psychosis treatment and provide resources for 
programs in how to address them. 
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good referral channels to medication-assisted 
treatment programs to ensure that their clients 
have access to the most effective evidence-
based treatment. Other community  
resources include self- and mutual-help 
programs, especially those with a focus 
on young adults and transition age youth. 
Individuals may best be served by specialized 
substance use disorder services coordinated 
with and by first-episode psychosis programs. 
The third task is to integrate a harm reduction 
approach that promotes both reduction of 
substance use and abstinence as treatment 
goals. In treatment based on a harm reduction 
approach, the overall focus is on reducing 
negative consequences and supporting person-
centered goals related to decreasing substance 
use. Administrators, clinicians, family members, 
and clients may all hold different beliefs about  
harm reduction versus abstinence, which can  
lead to misunderstandings and unclear 
expectations for treatment. 
Given the complexity of first-episode psychosis 
and its treatment, it is important for programs 
and clinicians to embrace and incorporate harm 
reduction as a guiding model for treatment. 
Young adults with lower severity of substance 
misuse can learn skills for limiting the quantity 
and frequency of substance use and ensure 
no use during high-risk times (such as while 
driving or at school or work), and those with 
higher severity who are not yet willing to 
discuss abstinence might agree to reduction 
in the context of important recovery goals, 
potentially leading to increased motivation for 
change and future abstinence. 
!2 Implementation Strategy #2
Utilize a quality improvement 
approach 
■■ Identify resources available to track services 
provided and ways to monitor the benefits 
and challenges of providing them 
■■ Become educated on electronic medical 
records or other automated systems that 
your program can use to collect service  
use information 
Current research does not provide robust support
for a standardized set of practices for treating
substance misuse/disorders in first-episode
psychosis. Thus, programs offer a variety of
services to clients and families. All programs
should adopt a quality improvement approach
to assess indicators of key treatment processes
in order to track the services provided, analyze
the pros and cons of these services, and improve
treatment by implementing services that benefit
clients and families.2 This ongoing inquiry and
self-examination allows programs to use their
own experiences to identify what is working or
not in their own treatment settings.
For a quality improvement approach to be 
successful, it is essential that programs collect 
data on the services offered, who uses these 
services, and service outcomes. Such data 
can help us understand which treatments 
work, which clients are benefiting, and which 
components of a program are not reaching 
clients or benefiting them. It is also an important 
way to advocate for more resources to address 
substance misuse/disorders. Programs can 
facilitate data collection in these ways: 
■ Integrate substance use measures as part 
of the electronic medical record with alerts 
that remind clinicians when to administer 
them and systems with built-in scoring and 
interpretation; 
41 
First-Episode Psychosis and Co-Occurring Substance Use Disorders
Guidance for Selecting and Implementing Evidence-Based Practices and Programs 
 
 ■
 ■■
 ■■
 ■■
 
 
 
 
 
 
 
 
 
 
 
!3 
■ Utilize mobile health applications or 
patient portal access to encourage clients 
to complete outcome measures; and 
Include assessments in automated forms 
that do not require additional time and 
effort to administer, enter, and score (a 
longer-term project that can help maintain 
the use of assessment over time). 
Implementation Strategy #3 
Build staff confidence and capacity 
Train program clinicians to assess and treat 
substance misuse/disorders 
Support clinicians as they work with young 
adults who are not motivated to change 
substance use 
Employ or refer to a Peer Specialist with 
lived experience of first-episode psychosis 
and co-occurring substance misuse/
disorders 
All clinicians in first-episode psychosis treatment 
programs should have basic training in assessing 
and treating substance misuse/disorders. 
Basic skills should include using a brief set of 
measures to assess quantity and frequency of 
use, providing feedback and recommendations 
in a person-centered and nonjudgmental way, 
and engaging individuals in recovery-oriented 
discussions about the impacts of continued 
substance misuse/disorders on progress towards 
goals. Training should be augmented by hiring 
several clinicians who can lead and sustain a 
program’s substance misuse/disorders treatment 
services or provide more advanced training or 
certification to existing staff. 
Advanced training can include instruction in 
diagnostic interviewing so that the program has 
a clear understanding of current and lifetime 
substance use disorders across substances. It 
can also include training in motivational and 
cognitive behavioral strategies demonstrating 
some evidence of effectiveness (see Chapter 
2 of this guide). Advanced training could also 
include certification in treatment for chemical 
dependency (this may be required in order 
to provide substance use treatment in some 
states). Creating tiered expertise ensures that 
all clinicians can address substance misuse/ 
disorders within first-episode psychosis  
services and that programs have specific 
expertise in addressing this common and 
impactful comorbidity. 
A gap in the research literature on first-episode 
psychosis treatment is the impact of Peer 
Recovery Specialists (peer specialists) as part 
of the treatment team. Peer specialists are 
widely integrated within substance use disorder 
treatment services3, 4 and have demonstrated 
positive outcomes. Evidence of the effectiveness 
of peer support services for adults with mental 
illnesses, particularly in areas such as hope, 
empowerment, and quality of life,6 suggests that 
peers can make valuable contributions to first-
episode psychosis treatment teams. 
5 
Peers can work with individuals experiencing 
first-episode psychosis to reduce stigma 
and improve self-determination, health and 
wellness, communication with other members 
of the treatment team, illness management, 
and engagement in first-episode psychosis 
services.7 Peer specialists who have lived 
experience of both mental health challenges 
and substance misuse/disorders are particularly
well-suited to support individuals in their
recovery efforts, as they can share first-hand
knowledge of the experience, demonstrate that
recovery is possible, and facilitate connections
with community-based resources. Family peer
support also holds promise for engaging families 
in first-episode psychosis services, enhancing
knowledge and caregiving skills, and promoting
recovery. Mounting support for the peer 
specialist workforce
8 
9-12 makes peers’ inclusion 
on first-episode psychosis treatment teams
increasingly feasible and encouraged.
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!4 Implementation Strategy #4
Assess and treat substance misuse 
and substance use disorders 
■■ Assess substance misuse/disorders at the 
start of treatment and on a regular basis to 
guide treatment 
■■ Use motivational and shared decision-
making approaches 
■■ Link substance misuse/disorder goals to 
the different components of first-episode 
psychosis services 
Collecting self-report data from young people 
about their substance use and problems over 
time provides necessary clinical information  
that is central to treatment planning, beginning 
with the very first clinical encounter. Young 
adults entering first-episode psychosis treatment 
will have different levels of severity of substance 
misuse/disorder; some will make significant 
reductions in substance use in the early stages 
of first-episode psychosis treatment without 
the need for any additional targeted treatment 
of substance misuse/disorders. Those who do 
not reduce their substance use in response to 
generalized first-episode psychosis treatment 
should be offered targeted substance use 
interventions. 
Many young adults experiencing first-episode 
psychosis may be hesitant or opposed to 
addressing co-occurring substance misuse/ 
disorders. Shared decision making (SDM) 
can help clients feel comfortable talking about 
substance use in treatment without tension 
or discomfort. Shared decision making is a 
collaborative process in which the individual 
and provider actively share knowledge to 
identify a preferred treatment approach.13 In 
SDM, the provider can offer information about 
treatments, while the client is asked to clarify 
his/her values and preferences as an active 
participant in the decision-making process.14 
It is critical to implement measures to assess 
substance use, both at the start of treatment 
and throughout the treatment process. Initial 
and ongoing assessment allows programs to 
track progress, target interventions, and allocate 
trained clinician time to clients who need it most. 
■ Programs can add screening measures for 
substance misuse/disorders to a program’s 
intake process (Chapter 5 of this guide 
provides examples of screening and other 
assessment tools). 
■ Those with a positive score on a screening 
measure for substance misuse/disorders 
should next complete a review of DSM-5 
criteria for recent substance use disorders. 
■ These assessments can be built into an 
existing intake process and administered 
monthly or quarterly as time permits. 
Most are self-report measures that can 
be filled out by clients as they wait for an 
appointment or can be administered via a 
computer or tablet. 
Studies utilizing SDM tools with individuals 
with serious mental illness (SMI) suggest 
that their participation in decision-making 
is feasible and that they can make informed 
decisions regarding their treatment.15, 16 In their 
discussion of strategies to engage individuals 
with psychotic disorders in care, Kreyenbuhl 
and colleagues17 identified SDM interventions 
as especially promising and specifically 
identified young adults experiencing early 
psychosis as a population that would benefit 
from SDM approaches. These authors 
reviewed studies of SDM interventions in SMI 
and found positive outcomes including better 
adherence, self-management, and satisfaction. 
Motivational approaches such as Motivational 
Enhancement Therapy (MET) and 
Screening, Brief Intervention, and Referral 
to Treatment (SBIRT) are also useful in 
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working with those who are ambivalent 
about change. MET is a brief intervention 
that helps individuals resolve ambivalence 
about substance use treatment and change. 
It involves assessment and feedback that 
encourages discussion of substance use,  
builds motivation, and allows for collaborative 
planning for change.18 
Similarly, SBIRT19 involves assessment 
and feedback within a supportive and non-
judgmental framework, and when used as part 
of an ongoing course of treatment, SBIRT
can be applied to addressing first-episode 
psychosis and co-occurring substance misuse/ 
disorders. SBIRT has been implemented 
in physical and mental health care settings 
that provide services to heavy or problem 
drinkers, including young adults.20,21 These 
programs utilize personalized feedback 
that is nonjudgmental, emphasizes personal 
responsibility for change, and offers 
individuals options for change.22 
All clinicians in first-episode psychosis 
treatment programs should be proficient in 
engaging in recovery-oriented discussions  
about the impacts of continued substance 
misuse/disorders on treatment goals. This 
allows clinicians to discuss substance use 
as part of their area of specialty within first-
episode psychosis services, linking reductions 
in use to recovery goals of strong importance  
to the client. Although a young adult client with 
first-episode psychosis may not be interested 
in reducing substance use per se, he or she may 
be interested in reducing psychosis symptoms, 
re-engaging in school, getting a job, or 
establishing independence from parents. 
All discussions with clients must be person-centered 
and respectful. If a client wants less discussion of 
substance use, the clinician should respect the client 
and put the topic on the “back burner” for some 
agreed-upon amount of time. 
These topics are not just the domain of an 
addictions counselor or recovery coach – 
they are central to the work of psychiatrists, 
psychologists, nurses, counselors, Supported 
Employment and Education Specialists, and 
Peer Specialists who work with young adults 
as part of first-episode psychosis treatment. 
For example, a Supported Employment and 
Education Specialist can help a young person 
plan for a job interview and provide a negative 
urine sample; this links reduction in substance 
use with the goal of securing employment. A 
counselor working with a young person who 
wants to develop skills for coping with anxiety 
can initiate a discussion of strategies to deal 
with anxiety and test the strategies out to see if 
they are helpful. 
!5 Implementation Strategy #5
Maintain the capacity of your 
program to assess and treat 
substance misuse and substance 
use disorders over time 
■■ Implement procedures to maintain 
knowledge on substance misuse/disorders 
within the program 
■■ Seek out ongoing consultation and/or join a 
first-episode psychosis learning collaborative 
Once assessments are integrated into the 
program and clinicians trained, it is essential 
to maintain this knowledge and expertise 
within the program. This can be challenging 
when administrative champions are deployed 
to other programs, specially trained staff leave 
for other jobs, and funding sources that support 
training efforts become scarce. A program can 
help ensure continued capacity to assess and 
treat substance misuse/disorders by ensuring 
that all staff receive at least basic training in the 
assessment and treatment of substance misuse/ 
disorders, making training and skill building 
in these areas a routine part of treatment team 
meetings, and prioritizing job candidates with 
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experience in providing substance use treatment
when hiring new staff. 
Any program’s work will be enhanced by 
consulting and collaborating with others. Find 
other programs that are doing this work and 
talk to them regularly. If a program is based on 
a CSC model, consultation resources may be 
available. State-funded CSC programs often 
develop learning collaboratives offering continued 
training and implementation updates. Establish 
relationships with other programs and consumer 
groups focusing on substance use disorders for 
continued learning; all parties can learn about 
first-episode psychosis and keep up to date on 
treatment advances.  
Common Implementation 
Barriers and Ways to 
Address Them 
The process of implementing integrated treatment 
for substance misuse/disorders within the context 
of first-episode psychosis services will vary from 
state to state, community to community, and 
program to program. There are no one-size-fits-all 
solutions for the barriers included in this section. 
The likely barriers, however, are common not only to 
programs serving people experiencing first-episode 
psychosis and substance misuse/disorders but also 
to many programs employing multiple coordinated 
interventions. The following includes suggestions on 
how programs may begin to address these barriers. 
Barrier #1: Financing Coordinated  
Specialty Care 
Financing CSC programs can be difficult because 
it requires funding an array of services that are not 
typically covered in full by either public or private 
health insurance.23 Medicaid can pay for therapy, 
case management, family support and education, 
psychopharmacology, and, in some states, supported 
employment and education or peer support. However, 
Medicaid does not cover community outreach or 
other program-related costs.24 Private insurance is 
highly important for young people experiencing 
first-episode psychosis as many can remain on their 
parents’ health insurance plans until age 26. However, 
private insurance focuses almost exclusively on 
fee-for-service payments that generally do not cover 
supported employment/education, case management, 
and some other services. While parity for mental 
health and substance use disorder treatment has 
improved, these individuals are most vulnerable. 
With other limitations from commercial health 
insurance plans, many states rely on additional 
funding sources such as the Mental Health Block 
Grant Ten Percent Set Aside, Section 1115 Medicaid 
demonstrations, or state funds for early intervention 
and CSC programs. States that develop 1115 
demonstration waivers can bundle all costs related 
to the program into a rate. While these waivers are 
complicated to develop, there is expertise in states that
have created bundled rate programs. As more CSC 
programs are implemented, it is likely that successful 
financing will include integrating different funding 
sources to fully cover the range of evidence-based 
first-episode psychosis services. Fortunately, the 
field is working towards finding solutions to these 
 
challenges.25 
Potential solutions:
■ Work with local jurisdictions to make use of 
and bridge available funding streams, given the 
differences in funding regulations and resources 
across states. 
■ Ensure that plans for sustainability are developed 
before grant and contract funding ends. 
■ Where applicable, a state Medicaid Authority 
can support first-episode psychosis programs by 
approving state Medicaid plan expansions and/or 
demonstration waivers to use Medicaid to cover 
needed CSC services. 
■ Funding for all behavioral health services has 
grown more complex as the trend towards 
integrated and holistic care accelerates.  Many
providers have become adept at accessing 
reimbursement from different sources to pay 
for complementary and coordinated services. 
Principles of braiding and blending funds for 
multicomponent services are transferable in 
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many cases. Developing expertise and gaining 
experience in handling funding from different 
sources is helpful for all provider agencies and 
necessary for sustaining a complex program such 
as CSC for first-episode psychosis and substance 
misuse/disorders. 
■ Starting in 2014, Congress expanded 
Mental Health Block Grant funding for 
Early Psychosis Coordinated Specialty 
Care programs nationwide, and the 2016 
21st Century Cures Act continued that 
commitment 
■ In 2017, the Interdepartmental Serious 
Mental Illness Coordinating Committee 
(ISMICC) issued recommendations that 
explicitly included national dissemination of 
early psychosis screening and intervention 
Barrier #2: Availability of trained staff for 
first-episode psychosis substance misuse/ 
disorder program 
Even programs with the best intentions fail if they 
are not staffed by individuals who understand their 
conceptual foundations and have the practical 
experience necessary to implement program goals.  
Yet staff training can be costly and is not always easily 
accessible. In some cases, providers may need specific 
licenses to treat substance misuse/disorders, adding 
another layer of difficulty to staffing these programs. 
Potential solutions: 
■ Emphasize training for program leadership on the 
importance of integrated substance use treatment 
for individuals with first-episode psychosis. 
■ Learn from other programs in your state or 
region implementing CSC for those experiencing 
first episode psychosis and substance misuse/ 
disorders. Refine understanding of staffing needs. 
■ Understand state licensing requirements for 
providers offering mental health and substance 
use treatment services. 
Innovative programs are most likely to succeed when 
staffed by creative, committed clinicians who are 
eager to learn from others tackling similar problems. 
Because the solutions offered here draw on the 
expertise of different disciplines, it is important for 
teams to be able to engage regularly and share their 
observations and experiences. 
Barrier #3: Limited research to guide practice 
A slim evidence base currently exists for substance 
misuse/disorders intervention in the context of first-
episode psychosis. Although research has led to the 
tremendous growth of CSC, much work remains to 
identify the best ways to address serious 
comorbidities such as substance misuse/disorders. 
How can we document successes and failures in 
addressing these issues? 
Potential solutions:
■ Connect with other programs in your state or 
region implementing CSC for those experiencing 
first-episode psychosis and substance misuse/ 
disorders and begin to create a community of 
practice. 
■ Form partnerships with academic institutions or 
researchers to promote demonstration projects or 
other activities that will expand the evidence base.
■ Gather information about practices that are 
useful in clinical settings to build the research 
base for these interventions, and share 
observations with others working in the field 
regionally and nationally. 
Barrier #4: Environmental considerations  
A program’s geographic location or the characteristics  
of the population it serves can make treatment of  
first-episode psychosis and substance misuse/disorders 
challenging. Particularly in rural environments, there 
may be limited availability of qualified staff who know 
how to effectively address substance misuse/disorders. 
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Potential solutions:
■ Ensure treatment program leadership understand 
the regional culture/local issues related to 
mental health and substance use and build 
staff consensus on how staff will address 
these local issues. 
■ Create and maintain collaborative relationships 
with substance use treatment providers, housing 
organizations, and education or employment 
specialty programs, if they exist in the region. 
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C H A P T E R  
5 
Resources for
Implementation,
Evaluation, and Quality
Improvement 
This chapter provides an array of resources about 
evidence-based practices and programs to address 
first-episode psychosis and substance misuse/ 
disorders. These resources include: 
1. screening and assessment instruments; 
2. service delivery guidelines for diagnoses and 
various treatment and practice approaches; 
3. implementation of Coordinated Specialty
Care; and 
4. informational resources for young adults 
and families. 
The goal of this resource list is to help clinicians 
and programs find tools, trainings, assessments, and 
interventions that they can integrate into existing 
services. This list is not exhaustive but aims to 
provide some key resources in several areas of 
greatest relevance to first-epsiode psychosis programs. 
Screening and 
Assessment 
Essential to effective practice for young adults with 
first-episode psychosis and co-occurring substance 
use disorders is the use of screening and assessment 
instruments for timely identification of symptoms, 
diagnosis, and appropriate treatment and services. 
Below are examples of screening and assessment tools 
that treatment providers can use in their practice. 
Mental Health and Substance Use 
■	 DSM-5 Self-Rated Level 1 Cross-Cutting 
Symptom Measure—Adult 
This self-report measure from the American 
Psychiatric Association assesses mental health 
domains that are important across psychiatric 
diagnoses. Domains VII and XIII pertain to 
Psychosis and Substance Use. 
■	 SAMHSA-HRSA Center for Integrated 
Health Solutions 
The Screening Tools page of the SAMHSA-
HRSA website provides a variety of screening 
resources about specific mental health and 
substance use conditions. 
Symptomatology and Functioning 
■	 Modified Colorado Symptom Index (CSI) 
This is a 14-item self-report scale of the 
frequency of positive mood and cognitive 
symptoms.1 
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■	 Social and Role Dysfunction in Psychosis 
and Schizophrenia 
This is a clinician-rated tool that assesses social 
and role functioning. Each question is scored on 
a 10-point scale and captures current functioning, 
lowest functioning over the past year, and highest 
functioning over the past year.2 
Substance Use 
■	 Addiction Severity Index (ASI) 
The ASI is a semi-structured interview designed 
to address seven potential problem areas: medical 
status, employment and support, drug use, 
alcohol use, legal status, family/social status, and  
psychiatric status. 
■	 Alcohol Use Disorders Identification Test 
(AUDIT) 
This is a 10-item screening questionnaire 
assessing excessive drinking and alcohol use 
disorders.3 
■	 American Society of Addiction Medicine 
(ASAM) 
The screening and assessment tools page on  
the ASAM website provides multiple  
assessment tools and resources on substance  
use for providers. 
■	 CAGE-AID 
The CAGE-AID is a four-item screening 
questionnaire on substance use. 
■	 CRAFFT Screening Interview 
The CRAFFT Screening Interview is a 
behavioral health screening tool designed for 
individuals under the age of 21 and is intended to 
identify adolescents who may have simultaneous 
risky alcohol and other drug use disorders.4 
■	 Drug Abuse Screening Test (DAST-10) 
Condensed from the 28-item DAST, this 10-item 
self-report questionnaire measures the degree of 
consequences related to drug abuse.5 
■	 Fagerström Test for Nicotine Dependence 
(FTND) 
The Fagerström Test for Nicotine Dependence is 
a standard instrument for assessing the intensity 
of physical addiction to nicotine.6 
■	 National Institute on Drug Abuse (NIDA) 
The Clinical Assessment of Substance Use 
Disorders page on the NIDA website provides 
screening, evaluation, and referral tools for 
addressing the needs of individuals with 
substance use disorders. 
■	 NIDA Modified ASSIST Drug Use 
Screening Tool 
This tool allows for a review of DSM-5 criteria 
for recent substance use disorders for individuals 
who have a positive screen for substance abuse. 
■	 PhenX Toolkit: Substances – 30-Day 
Frequency 
This tool measures the frequency of drug use 
over 30 days.7 
■	 Simple Screening Instrument for Substance 
Abuse (SSI-SA) 
The SSI-SA is a 16-item screening instrument 
designed to capture a broad spectrum of signs 
and symptoms for substance use disorders.8 
■	 Substance Abuse and Dependence – 
Past Year – Alcohol 
This interview protocol includes questions about 
alcohol experiences in the past 12 months.9 
■	 UNCOPE 
The UNCOPE consists of six questions to 
identify risk for abuse and dependence for 
alcohol and other drugs. 
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Service Delivery Guides 
Giving treatment providers the necessary tools and 
resources to effectively deliver treatment is critical 
to the successful implementation of programs and 
services as well as enhancing treatment engagement 
among clients. Below are examples of practice  
guides to help treatment providers learn about early 
warning signs of psychosis, identify appropriate 
interventions and treatment, promote culturally 
appropriate practices, and keep up with evidence-
based research and practice principles on various 
treatment approaches. 
Assessment and Diagnosis 
■	 Age and Developmental Considerations in 
Early Psychosis 
This issue brief explores how to recognize and tailor 
early psychosis programs to developmental challenges 
and opportunities to maximize program effectiveness. 
■	 Alcohol Screening and Brief Intervention for 
Youth: A Practitioner’s Guide 
Published by the National Institute on Alcohol Abuse 
and Alcoholism, this guide offers providers resources 
for identifying youth with alcohol-related problems. 
■	 Early Interventions in Psychosis: A Primer 
This online course is designed for professionals 
working with teens and young adults who are 
interested in learning about the early warning signs 
of psychosis, appropriate early intervention treatment 
and supports, and strategies for successfully engaging 
youth in effective, recovery-oriented care. 
■	 Substance-Induced Psychosis in First Episode 
Programming 
An overview of the epidemiology, presentation, 
diagnosis, and treatment of individuals with 
substance-induced psychosis who may be seen in 
first-episode psychosis programs. 
Treatment Approaches and Techniques 
■	 Addiction Technology Transfer Center 
(ATTC) Network 
The ATTC Network is an international, 
multidisciplinary resource for professionals in the 
addictions treatment and recovery services fields. 
■	 Cognitive Behavioral Therapy for Psychosis 
(CBTp) 
This factsheet from the National Association 
of State Mental Health Program Directors 
(NASMHPD) provides an overview of the 
principles and practices of CBTp, with case 
examples illustrating each of its key components. 
■	 Integrated Dual Disorder Treatment (IDDT) – 
Clinical Guide 
This training booklet is part of a consulting and 
training process on Integrated Dual Disorder 
Treatment from the Center for Evidence-Based 
Practices (CEBP) at Case Western Reserve 
University. 
■	 Optimizing Medication Management for 
Persons Who Experienced a First Episode 
of Psychosis 
This is a shared decision-making tool for making 
decisions regarding use of medications. 
■	 NAVIGATE’s Individual Resiliency 
Trainer Manual 
This manual includes modular-based 
interventions for helping individuals identify and 
enhance their strengths and resiliency, increase 
their illness management skills, and learn skills 
to increase their success in achieving personal 
goals. Module 10 focuses on substance use. 
■	 SAMHSA’s Integrated Treatment for Co-
Occurring Disorders Evidence-Based 
Practices (EBP) KIT 
This toolkit gives practice principles for 
integrated treatment for mental illness and 
substance use disorders and offers advice from 
successful programs. 
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■	 Screening, Brief Intervention, and Referral to 
Treatment (SBIRT) 
SBIRT is an evidence-based practice used to 
identify, reduce, and prevent problematic use, 
abuse, and dependence on alcohol and illicit 
drugs. SBIRT can be used as part of a continued 
course of treatment for first-episode psychosis 
and co-occurring substance misuse/disorders. 
It provides a supportive and nonjudgmental 
framework for discussing risky substance use, its 
consequences, and person-centered reasons for 
reducing risky use to improve health. 
■	 Supported Education for Persons 
Experiencing a First Episode of Psychosis 
This issue brief is a primer on the rationale for 
and techniques involved in delivering  
supported education services in first-episode 
psychosis programs. 
Improving Cultural Competence 
■	 APA’s Cultural Formulation Interview (CFI) 
The CFI is a short questionnaire that aims to 
enhance clinical understanding and decision 
making by clarifying key aspects of the 
presenting clinical problem from the point of 
view of the client or other members of the client’s 
social network. 
■	 National Center for Cultural Competence 
(NCCC) Self-Assessments 
The NCCC at Georgetown University offers a 
variety of organizational self-assessments to 
evaluate cultural and linguistic competence. 
Results of such self-assessments may be used 
to summarize strengths and areas for growth 
to advance cultural and linguistic competence, 
strategic planning, and program quality 
improvement. 
■	 Treatment Improvement Protocol: Improving 
Culture Competence 
This resource is intended to help clinicians, 
practitioners, and behavioral health organizations 
make progress toward cultural competence. 
Coordinated Specialty 
Care Implementation 
Over the last decade, Coordinated Specialty Care 
(CSC) has gained support as an evidence-based 
treatment model for first-episode psychosis. Examples
of guidelines and briefs to assist organizations in 
implementing and adapting CSC are provided below. 
 
■	 Coordinated Specialty Care for People with 
First Episode Psychosis: Assessing Fidelity to 
the Model 
This issue brief reviews the importance of 
measuring implementation fidelity, lists the 
core components of CSC to monitor via fidelity 
measures, suggests potential data sources for 
measuring these core components and reviews 
how data from these sources can be aggregated 
into measures of CSC fidelity. 
■	 Early Intervention in Psychosis Virtual 
Resource Center 
NASMHPD Early Intervention in Psychosis 
virtual resource center is designed to provide 
reliable information for practitioners, 
policymakers, individuals, families, and 
communities to foster more widespread adoption 
and utilization of early intervention programming 
for persons at risk for or experiencing a first 
episode of psychosis. 
■	 First Episode Psychosis Fidelity Scale 
(FEPS-FS) 
This 32-item fidelity scale covers assessment 
and monitoring, pharmacotherapy, psychosocial 
treatments, and team structure and function. 
■	 First Episode Psychosis Programs: A Guide to 
State Expansion 
The National Alliance on Mental Illness (NAMI) 
created a guide to help state organizations 
facilitate implementation of CSC programs
across the country. 
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■	 Trainings on First-Episode Psychosis 
NASMHPD website has a variety of online 
trainings available for clinicians, providers, and 
families on early psychosis and coordinated 
specialty care. 
■	 Webinars on Topics Related to First-
Episode Psychosis 
NASMHPD has assembled a variety of 
informational webinars on a number  
of topics, including first-episode psychosis  
and treatment. 
■	 OnTrack Training Materials 
OnTrack NY provides a variety of manuals and 
an interactive tool to estimate costs and staffing 
for CSC Teams. 
■	 Treating Affective Psychosis and Substance 
Use Disorders within Coordinated 
Specialty Care 
This brief describes several adaptations and 
recommendations that CSC teams may consider 
to enhance the effectiveness of the specialized 
treatment mode. 
Informational Resources
for Young Adults and 
Families 
Providing young adults and their families with 
supports and resources about first-episode psychosis 
may help alleviate the fear, stress, and uncertainty  
that they experience. Information about early 
psychosis symptoms, substance use, availability and 
access to treatment, different treatment approaches, 
and strategies for living with psychosis may help 
young adults and their families get timely and 
appropriate treatment. 
Treatment Locator 
■	 EASA’s Program Directory of Early Psychosis 
Intervention Programs 
A directory of early intervention programs for 
psychosis within the United States. 
■	 SAMHSA’s Early Serious Mental Illness 
Treatment Locator 
Provides a confidential and anonymous source 
of information for persons and their family 
members who are seeking treatment facilities 
in the United States or U.S. Territories for a 
recent onset of serious mental illnesses such as 
psychosis, schizophrenia, bipolar disorder, and 
other conditions. 
Tip and Fact Sheets on First-Episode 
Psychosis 
■	 NAVIGATE Family Education Program 
Pages 86-180 of this manual include “JUST 
THE FACTS” educational handouts for family 
members and relatives of individuals who have 
experienced first-episode psychosis. 
■	 NIMH First Episode Psychosis Fact Sheet 
This resource offers facts about psychosis and 
descriptions of treatments used in Coordinated 
Specialty Care. 
■	 RAISE Resources for Patients and Families 
This tool provides descriptions of first-episode 
psychosis, treatment options, and strategies for 
living with psychosis. 
■	 Understanding First Episode Psychosis: 
Caregiver Tip Sheet 
This fact sheet provides an overview of psychosis 
among youth and young adults. It offers guidance 
on how to provide support and recommendations 
for treatment. 
■	 Understanding First Episode Psychosis: 
Young Adult Tip Sheet 
This fact sheet offers young adults information 
on living with psychosis. It discusses the causes 
of psychosis and approaches to treatment. 
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Tip and Fact Sheets on Substance Use 
■	 DrugFacts 
The National Institute on Drug Abuse has 
developed these brief, plain language research 
summaries on different types of drugs. 
■	 Mind Matters 
This youth-focused series developed by the 
National Institute on Drug Abuse includes scientific 
information about different types of drugs. 
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